HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $7
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and raises the price target from $4 to $7.
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and raises the price target from $4 to $7.